Page 57 - Read Online

Tanasanvimon. J Cancer Metastasis Treat 2018;4:57 I http://dx.doi.org/10.20517/2394-4722.2018.38 Page 11 of 11

68. van Geel R, Tabernero J, Elez E, Bendell JC, Spreafico A, et al. A phase Ib dose-escalation study of Encorafenib and Cetuximab with or
without alpelisib in metastatic BRAF-mutant colorectal cancer. Cancer Discov 2017;7:610-9.
69. Atreya CE, Van Cutsem E, Bendell JC, Andre T, Schellens JHM, et al. Updated efficacy of the MEK inhibitor trametinib (T), BRAF
inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic
colorectal cancer (mCRC). J Clin Oncol 2015;33:abstr103.
70. Richman SD, Southward K, Chambers P, Cross D, Barrett J, et al. HER2 overexpression and amplification as a potential therapeutic
target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol
2016;238:562-70.
71. Lee WS, Park YH, Lee JN, Baek JH, Lee TH, et al. Comparison of HER2 expression between primary colorectal cancer and their
corresponding metastases. Cancer Med 2014;3:674-80.
72. Takegawa N, Yonesaka K, Sakai K, Ueda H, Watanabe S, et al. HER2 genomic amplification in circulating tumor DNA from patients with
cetuximab-resistant colorectal cancer. Oncotarget 2016;7:3453-60.
73. Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, et al. Assessment of a HER2 scoring system for colorectal cancer:
results from a validation study. Mod Pathol 2015;28:1481-91.
74. Hurwitz H, Raghav KPS, Burris HA, Kurzrock R, Sweeney C, et al. Pertuzumab + trastuzumab for HER2-amplified/overexpressed
metastatic colorectal cancer (mCRC): Interim data from MyPathway. J Clin Oncol 2017;35:abstr676.
75. Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S, et al. ALK, ROS1, and NTRK rearrangements in metastatic colorectal
cancer. J Natl Cancer Inst 2017;109.
76. Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, et al. Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor
entrectinib: combined results from two phase i trials (ALKA-372-001 and STARTRK-1). Cancer Discov 2017;7:400-9.
77. Amatu A, Somaschini A, Cerea G, Bosotti R, Valtorta E, et al. Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal
cancer. Br J Cancer 2015;113:1730-4.
78. Sartore-Bianchi A, Ardini E, Bosotti R, Amatu A, Valtorta E, et al. Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene
fusion in metastatic colorectal cancer. J Natl Cancer Inst 2016;108.
79. Brannon AR, Vakiani E, Sylvester BE, Scott SN, McDermott G, et al. Comparative sequencing analysis reveals high genomic concordance
between matched primary and metastatic colorectal cancer lesions. Genome Biol 2014;15:454.
80. Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, et al. Comparative genomic analysis of primary versus metastatic colorectal
carcinomas. J Clin Oncol 2012;30:2956-62.
81. Bertucci F, Finetti P, Guille A, Adelaide J, Garnier S, et al. Comparative genomic analysis of primary tumors and metastases in breast cancer.
Oncotarget 2016;7:27208-19.
82. Haraldsdottir S, Roth R, Pearlman R, Hampel H, Arnold CA, et al. Mismatch repair deficiency concordance between primary colorectal
cancer and corresponding metastasis. Fam Cancer 2016;15:253-60.
83. Jung J, Kang Y, Lee YJ, Kim E, Ahn B, et al. Comparison of the mismatch repair system between primary and metastatic colorectal cancers
using immunohistochemistry. J Pathol Transl Med 2017;51:129-36.
84. Agoston EI, Baranyai Z, Dede K, Bodoky G, Kulka J, et al. Occurrence, intratumoral heterogeneity, prognostic and predictive potential
of microsatellite instability following surgical resection of primary colorectal carcinomas and corresponding liver metastases. Orv Hetil
2015;156:1460-71.
85. Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A. Changes in mutational status during third-line treatment for metastatic colorectal
cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Int J Cancer 2014;135:2215-22.
86. Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, et al. Clinical validation of the detection of KRAS and BRAF
mutations from circulating tumor DNA. Nat Med 2014;20:430-5.
87. Bachet JB, Bouche O, Taieb J, Dubreuil O, Garcia ML, et al. RAS mutation analysis in circulating tumor DNA from patients with metastatic
colorectal cancer: the AGEO RASANC prospective multicenter study. Ann Oncol 2018;29:1211-9.
88. Tie J, Kinde I, Wang Y, Wong HL, Roebert J, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with
metastatic colorectal cancer. Ann Oncol 2015;26:1715-22.
89. Garlan F, Laurent-Puig P, Sefrioui D, Siauve N, Didelot A, et al. Early evaluation of circulating tumor dna as marker of therapeutic efficacy
in metastatic colorectal cancer patients (PLACOL study). Clin Cancer Res 2017;23:5416-25.
90. Diaz LA, Jr., Williams RT, Wu J, Kinde I, Hecht JR, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in
colorectal cancers. Nature 2012;486:537-40.
91. Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, et al. The consensus molecular subtypes of colorectal cancer. Nat Med
2015;21:1350-6.